Home > Boards > US Listed > Biotechs >

Vical Inc. (VICL)

Add VICL Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 8/30/2019 4:30:30 PM - Followers: 66 - Board type: Free - Posts Today: 0


Corporate Profile

DNA Technology

Vical's proprietary core technology is based on plasmid DNA (pDNA), closed loops of DNA that encode any protein of interest. When injected into tissues such as skeletal muscle or the skin, cells take up pDNA and produce the encoded protein. This allows for pDNA to be used as the basis for a broad range of biopharmaceutical products: infectious disease vaccines (delivering antigens from viruses, bacteria, or parasites), cancer vaccines or immunotherapeutics (delivering tumor antigens or immunostimulatory proteins), and growth factors to stimulate angiogenesis and tissue repair in diseases such as cardiovascular disorders.

Since its initial discovery, Vical has continued to improve its DNA delivery technology so as to maximize gene expression as well as the body's response to the proteins produced. For example, we optimize the DNA sequences that make up our pDNA, and we continue to develop new formulation and delivery technologies, including the use of lipid molecules (which can function as vaccine adjuvants) and synthetic polymers such as poloxamers.

Plasmids are manufactured in Vical's cGMP facility in San Diego using uniform methods of bacterial fermentation and processing, which allows faster development and production times than technologies that require development of product-specific processes. In addition, since our product candidates contain no viral components they are designed to avoid unwanted immune responses, infections, or malignant changes in a cell's genetic makeup, and have been administered repeatedly with a very favorable safety profile in clinical trials to date.


Independent Programs

HSV-2 Vaccine (Phase1/2)

Corporate Collaborations

ASP0113 for HCT (Astellas Pharma)
ASP0113 for SOT (Astellas Pharma)
By United States Department of AgricultureONCEPT™ Canine Melanoma Vaccine (Merial)

Government Collaborations


Clinical Trials Overview

Vical has filed thirteen investigational new drug applications to conduct clinical trials and holds four master files for manufacturing recombinant DNA products.

Vical has completed more than thirty clinical trials with recombinant DNA products. These Phase 1 – Phase 3 trials of vaccines or gene therapy products have been conducted in up to 15 countries.

Check back frequently for updates on future enrollments or connect with us through RSS Feeds or connect with us on Vical on LinkedIn or Vical on Twitter.

Infectious Disease Vaccine Trials

Phase 3 Clinical Trial: ASP0113 Therapeutic Cytomegalovirus (CMV) Vaccine
A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT). For more information, please go to the NCT01877655 trial listing at ClinicalTrials.gov.

Phase 2 Clinical Trial: ASP0113 Therapeutic Cytomegalovirus (CMV) Vaccine 1
A Study to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ From a CMV-Seropositive Donor. For more information, please go to the NCT01974206 trial listing at ClinicalTrials.gov.

Phase 1/2 Clinical Trial: Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Phase 1/2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 Therapeutic DNA Vaccines in Symptomatic HSV-2-Seropositive Adults. For more information, please go to the NCT02030301 trial listing at ClinicalTrials.gov. ?

Investor Overview


By synergizing vaccine and DNA technologies, Vical is creating new therapies, and shaping the future of vaccines.  Our vision is to realize the promise of novel preventive and therapeutic alternatives for serious and life-threatening diseases.


$VICL recent news/filings 
Many thanks to stocktrademan  for post #774



Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
VICL News: Current Report Filing (8-k) 10/09/2019 07:01:50 AM
VICL News: Statement of Beneficial Ownership (sc 13d) 09/16/2019 04:23:23 PM
VICL News: Securities Registration: Employee Benefit Plan (s-8) 09/10/2019 04:23:32 PM
VICL News: Current Report Filing (8-k) 09/03/2019 07:03:33 AM
VICL News: Vical Stockholders Approve Reverse Stock Split and Merger with Brickell 08/30/2019 11:54:51 AM
#1016   * * $VICL Video Chart 08-30-2019 * * ClayTrader 08/30/19 04:30:30 PM
#1015   "Take a look at me know".... dhe777 08/16/19 03:54:27 PM
#1014   * * $VICL Video Chart 06-03-2019 * * ClayTrader 06/03/19 04:10:56 PM
#1013   On watchlist... Obelax 06/03/19 05:04:30 AM
#1012   Plunging this one under a buck - showing RNsidersbuying 01/16/19 09:54:56 AM
#1011   VICL Ongoing trial completion date December 19, 2019. Echo20 10/25/18 10:10:48 AM
#1010   VICL VICL keeps buying and selling. Echo20 10/24/18 10:53:00 AM
#1009   Klinsmann Looks like VICL could have some potentials. Echo20 10/16/18 01:32:23 PM
#1008   Klinsmann Just to see if you have any added Echo20 10/11/18 11:00:32 AM
#1007   Zorry, no insider information. Just charts and possible Klinsmann 10/10/18 03:37:34 PM
#1006   Klinsmann Do you see any good news and results Echo20 10/10/18 02:56:53 PM
#1005   Bullish chart but volume missing... Klinsmann 10/08/18 11:42:36 AM
#1004   Klinsmann Moving up slightly! Echo20 10/08/18 11:26:14 AM
#1003   Thx! I still like the setup here - Klinsmann 10/08/18 10:00:07 AM
#1002   Klinsmann Best of success. Echo20 10/08/18 09:57:04 AM
#1001   Still here my friend. Gonna enter, looking strong. Klinsmann 06/18/18 04:33:23 PM
#1000   Klinsman Huh? Not many posters here this year. Echo20 Echo20 06/18/18 04:12:48 PM
#999   On close watch, gonna last some time to Klinsmann 06/12/18 07:39:49 AM
#998   Any one here? Vicl going up? Echo20 Echo20 05/09/18 03:13:44 PM
#997   Mostly corporate investments? Echo2o Echo20 04/12/18 02:51:21 PM
#996   VICL Notice these posts are all very old? Echo20 03/21/18 01:29:24 PM
#995   That +150k buy block on Friday....well well well....that Blade$dream 01/22/18 04:00:48 AM
#994   Lots of insider buying today. goldenisla 01/10/18 08:09:38 PM
#993   Any Happy New Year's projections for VICL? Echo20 Echo20 01/02/18 09:55:33 AM
#992   Bought some more today , big gains coming ! Joeymc77 11/22/17 04:14:42 PM
#991   Thoughts on next week ? Joeymc77 11/18/17 11:33:55 AM
#990   2 fiddy by EOW HeenTeHmachine 11/13/17 07:17:54 AM
#989   Is vicl going up now? How far? Echo20 Echo20 11/10/17 10:15:10 AM
#988   Grand Master's Going up? Echo20 Echo20 11/09/17 12:32:39 PM
#987   Chart lookin good! Grandmasters 10/10/17 11:11:21 AM
#986   INTL Go VICL and SANJAY. Echo20 10/04/17 05:23:28 PM
#985   goodplenty100 Big win for VICL and Sanjay. Echo20 10/04/17 04:43:00 PM
#984   Opinionator Great news. Keep it up VICL. Echo20 10/03/17 04:37:47 PM
#983   BUY HOLD BUY HOLD BUY HOLD ACCUMULATE Opinionator 10/03/17 01:22:26 PM
#982   goodplenty100 10/03/17 12:39:14 PM
#981   Price will settle Grandmasters 10/03/17 12:24:17 PM
#980   Great Company Grandmasters 10/03/17 12:23:27 PM
#979   3.57 PM buckiii2 10/03/17 07:55:01 AM
#978   I got alerted late about the news .. Sunnycupid 10/03/17 04:25:04 AM
#977   I got lucky and got Dec 3 calls buckiii2 10/02/17 07:04:46 PM
#976   VICL Over 20 times the average volume. Float INTL 10/02/17 06:54:46 PM
#975   Wow up big time AH. 1 m vol. buckiii2 10/02/17 06:28:27 PM
#974   Yes Like the setup on this one. INTL 10/02/17 06:24:52 PM
#973   I got in today just in the nick buckiii2 10/02/17 06:14:02 PM
#972   VICL Low float monster with big catalyst AH. INTL 10/02/17 05:50:14 PM
#971   VICL Bids stacking up AH. Big news! Bullish INTL 10/02/17 05:46:43 PM
#970   Tough Are the new products any good? Echo20 Echo20 07/18/17 02:36:04 PM
#969   WHy are all of these messages one year old? Echo20 07/14/17 03:46:55 PM
#968   It's all about selling on the news I Tough_to_make_money 06/20/16 06:07:07 PM
#966   Shareholders may need to worry about support levels, lemmy 06/20/16 04:37:58 PM